Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med Life's change in receivables for the quarter that ended in Mar. 2026 was lei-36 Mil. It means Med Life's Accounts Receivable
increased by lei36 Mil
from Sep. 2025 to Mar. 2026 .
Med Life's change in receivables for the fiscal year that ended in Dec. 2024 was lei-82 Mil. It means Med Life's Accounts Receivable
increased by lei82 Mil
from Dec. 2023 to Dec. 2024 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Med Life's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 34.66.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Med Life's liquidation value for the
three
months ended in Mar. 2026 was lei-2,278 Mil.
Med Life (LTS:0RO5) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Med Life's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life Change In Receivables Related Terms
Med Life Change In Receivables Historical Data
* Premium members only.
The historical data trend for Med Life's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei-56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of lei-56 Mil mean?
Med Life (LTS:0RO5) has a Change In Receivables of lei-56 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Med Life and its competitors.
Is Med Life's Change In Receivables too high?
Med Life's current Change In Receivables is lei-56 Mil. Overall, Med Life has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Change In Receivables compare to HCA and THC?
Med Life's Change In Receivables of lei-56 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Med Life and its competitors. Med Life's current Change In Receivables is lei-56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.51, compared to a current price of lei11.62 — trading 669.5% above its estimated fair value. The current Change In Receivables is lei-56 Mil. Med Life's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current Change In Receivables is lei-56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.62 is trading 669.5% above its estimated GF Value™ of lei1.51.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
Change In Receivables: lei-56 Mil
GF Value™: lei1.51 vs. price of lei11.62 (669.5% above fair value)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
62GF Score
Get the complete analysis for LTS:0RO5
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
